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Abstract
Background
Immune activation plays a key role in HIV pathogenesis. Markers of inflammation have
been associated with vitamin D deficiency in the general population. Studies have also dem-
onstrated associations of vitamin D deficiency with increased risk of HIV progression and
death. The relationship between persistent inflammation and immune activation during
chronic HIV infection and vitamin D deficiency remains unclear.
Methods
Cryopreserved specimens were analyzed from 663 participants at the time of enrollment
from the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Ther-
apy (SUN Study) from 2004 to 2006. Biomarkers of inflammation, atherosclerosis, and
coagulation were measured using enzyme-linked immunosorbent assays (ELISAs) and
electrochemiluminescence. 25(OH)D, the stable precursor form of vitamin D, was measured
using a radioimmunoassay with levels defined as: normal (30ng/mL), insufficient (20–29
ng/mL) and deficient (<20 ng/mL). Monocyte phenotypes were assessed by flow cytometry.
Linear and logistic regression models were used to determine statistical associations
between biomarkers and vitamin D deficiency.
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Results
25(OH)D levels were deficient in 251 (38%) participants, insufficient in 222 (34%), and nor-
mal in 190 (29%). Patients with vitamin D deficiency, when compared to those with insuffi-
cient or normal vitamin D levels, had increased levels of IL-6 (23%; p<0.01), TNF-α (21%,
p = 0.03), D-dimer (24%, p = 0.01), higher proportions of CD14dimCD16+ (22%, p<0.01) and
CX3CR1+ monocytes (48%; p<0.001) and decreased frequency of CCR2+ monocytes
(-3.4%, p<0.001). In fully adjusted models, vitamin D associations with abnormal biomarker
levels persisted for IL-6 levels and CX3CR1+ and CCR2+ phenotypes.
Conclusions
Vitamin D deficiency is associated with greater inflammation and activated monocyte phe-
notypes. The role of vitamin D deficiency in persistent immune activation and associated
complications during chronic HIV disease should be further evaluated as a possible target
for intervention.
Introduction
Studies continue to elucidate the role of vitamin D, both its prohormone and its more stable
circulating precursor, 25-hydroxyvitamin D (25(OH)D), in inflammatory diseases. Recent
data have shown that severe vitamin D deficiency is associated with an increased risk of
human immunodeficiency virus (HIV) disease progression and death[1], as well as elevated
levels of interleukin-6 (IL-6)[2, 3], a biomarker of innate immune activation. IL-6 elevations
have previously been shown to predict mortality and risk for non-AIDS-defining complica-
tions among persons with chronic HIV infection[4, 5].
Previous work by our group investigating inflammation in HIV-infected adults has shown
biomarkers of innate immune activation correlate strongly with monocyte activation pheno-
types and only modestly with phenotypes of T-cell maturation, but not with markers of CD8
T-cell activation[6]. In addition, monocyte activation was independently associated with pro-
gression of coronary artery calcifications after adjusting for traditional cardiac risk factors[7].
In the present analysis, our aim was to evaluate the associations of vitamin D deficiency with
cellular phenotypes of adaptive and innate immune activation to further explore the mechanis-
tic pathways linking vitamin D with innate immunity and the chronic inflammation that per-
sists in treated HIV infection.
Methods
Study design
The Study to Understand the Natural History of HIV/AIDS in the Era of Effective Antiretrovi-
ral Therapy (the SUN Study) was a Centers for Disease Control and Prevention (CDC)-funded
prospective observational cohort study of HIV-infected participants enrolled in four United
States (U.S.) cities (Denver, Minneapolis, Providence, and St. Louis) between March 2004 and
August 2006[8]. The protocol was approved by the institutional review boards of the CDC (the
CDC IRB-B) and each participating institution(Hennepin County Medical Center, Park Nicol-
let Hospitals and Clinics, Abbott Northwestern Hospital, Miriam Hospital, Washington Uni-
versity, and Denver Infectious Disease Consultants). All participants provided written
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informed consent. (NCT #00146419) Eligible participants were expected to survive at least two
years and were either treatment naïve or exposed solely to combination ART ( 3 nucleoside
reverse transcriptase inhibitors [NRTI] or 3 antiretroviral drugs from at least 2 different
classes).
Clinical data, including all medications and diagnoses, were extracted from medical charts
and entered into a single database (Clinical Practice Analyst; Cerner Corporation, Vienna,
VA). Additional data were collected through study-specific physical examinations, laboratory
testing, and an audio computer-assisted self-interview[8].
Specimen collection and laboratory measurements
At study entry, fasting whole blood and plasma specimens were collected and shipped over-
night to the CDC. Peripheral blood mononuclear cells (PBMC) were isolated and cryopre-
served centrally at a CDC lab within 30 hours of blood draw. All specimens were then stored
in liquid nitrogen at -70˚C until analyzed. Clinical site laboratory testing included measure-
ment of fasting serum lipids, plasma HIV RNA viral load (VL), and CD4 cell counts.
Measurement of biomarkers in cryopreserved plasma
All biomarkers were measured on the study entry specimens. Vitamin D was measured as 25
(OH)D with the 25(OH)D iodine 125 radioimmunoassay (Diasorin, Saluggia, Italy). The fol-
lowing soluble biomarkers were measured at the Diabetes Research and Training Center
Radioimmunoassay Core Laboratory (Washington University School of Medicine): IL-8 (BD
Biosciences, San Jose, CA) using an ezyme-linked immunosorbent assay (ELISA) based assay,
as well as hsCRP (Kamiya Biomedical Company, Seattle, WA) and D-dimer (Roche Diagnos-
tics, Indianapolis, IN) using immunoturbidometric assays on a Hitachi 917 analyzer. We mea-
sured sCD14 using an ELISA based assay (R&D Systems, Minneapolis MN). Tumor necrosis
factor (TNF)-α was measured using chemiluminescence on the Immulite 1000 (Erlangen, Ger-
many). The following biomarkers were measured at the National Institutes of Allergy and
Infectious Diseases: IL-6 (Meso Scale Discovery, Rockville, MD) using electrochemilumines-
cence immunoassays and sCD163 (Aviscera Bioscience, Inc., Santa Clara, CA) using an ELISA
based assay.
Immunophenotyping of PBMC
Immunophenotyping was performed on cryopreserved PBMC on the study entry specimens
using multi-color flow cytometry as previously described[6]. The fluorochrome-conjugated
antibodies used to evaluate monocyte phenotypes were: anti-CD2 efluor450 (Clone:RPA-
2.10), anti-CD3 efluor450 (clone:UCHT1), anti-CD19 efluor450 (Clone:HIB19), anti-CD20
APC (Clone:2H7), and anti-HLADR efluor605 (Clone:LN3) from eBioscience; anti-CX3CR1
APC (Clone:2A9-1), anti-CD16 PE-Cy7 (Clone:3G8), and anti-CCR2 PerCp-Cy5.5 (Clone:
TG5) from BioLegend; anti-CD14 PE (Clone:M5E2) and anti-CCR5 APC-Cy7 (Clone:2D7)
from BD Biosciences, anti-TF FITC (Clone:VIC7) from American Diagnostica; and Live/Dead
Fixable Blue Dead Cell Stain Kit with Ultra Violet (UV) excitation from Invitrogen.
The fluorochrome-conjugated antibodies used to evaluate T-cell phenotypes: anti-CD38
PE-Cy7 (Clone:HIT2), anti-CX3CR1 PE (Clone:2A9-1), anti-CD28 PE-Cy7 (Clone:CD28.2),
and anti-CD4 efluor605 (Clone:OKT4) from eBioscience, anti-CD57 APC (Clone:HCD57)
and anti-CD27 Ax700 (Clone:O323) from BioLegend, anti-HLADR PE (Clone:G46-6), anti-
CD3 APC-Cy7 (Clone:SK7), anti-CD8 PB (Clone:RPA-T8), and anti-CD56 PB (Clone:B159)
from BD Biosciences, and anti-CD45RO ECD (Clone:UCHL1) from Beckman Coulter.
Vitamin D and monocyte activation
PLOS ONE | https://doi.org/10.1371/journal.pone.0175517 May 2, 2017 3 / 11
Samples were acquired on an LSR-II flow cytometer (Becton Dickinson, Franklin Lakes,
NJ) and data were analyzed using FlowJo software version 9.3.3 (Treestar Inc., Ashland, OR).
The proportion of monocytes are expressed as a percent, with the following cell types charac-
terized: classical monocyte phenotype (CD14++CD16-), intermediate monocyte subset
(CD14+CD16+), or patrolling monocytes (CD14dimCD16+), monocytes expressing tissue fac-
tor (TF), and monocytes expressing markers of tissue migration (CCR2+ and CX3CR1+).
Gates were established as previously described [6]. All samples had >75% viability; only live
cells were included in all analyses.
Statistical methods
Participants’ vitamin D levels at study entry were categorized as normal (30ng/mL), insuffi-
cient (20–29 ng/mL) or deficient (<20 ng/mL) per the United States Endocrine Society[9].
Study entry characteristics were summarized with frequencies or medians and interquartile
ranges (IQR), as appropriate. Demographic data were compared among the three vitamin D
groups with the chi-square and Kruskal-Wallis tests. For each biomarker and monocyte popu-
lation the overall strength of association with concentration of vitamin D was determined with
Spearman’s correlation. The biomarkers were normalized for analysis with a log2 transforma-
tion. The relative percent difference between those with deficient versus non-deficient vitamin
D levels was assessed with general linear models. Finally, univariate and multivariable logisitic
regression models were used to explore the associations with biomarkers and vitamin D defi-
ciency (<20ng/mL). Odds ratios expressing the risk of vitamin D deficiency per doubling of
the biomarker were calculated with their corresponding 95% confidence intervals. Multivari-
able models were adjusted for baseline covariates that differed between vitamin D groups: age,
gender, race, Body Mass Index (BMI), treatment for hypertension (HTN), non-nucleoside
reverse transcriptase inhibitor (NNRTI) regimen, CD4 cell count, and time since HIV
diagnosis.
Results
Participant characteristics
Sufficient study entry plasma and PBMCs were available for 663 out of 700 participants. Vita-
min D levels were deficient for 251 (38%) participants, insufficient for 222 (34%), and normal
for 190 (29%) (Table 1). As has been previously reported in Dao et al [10], SUN Study partici-
pants differed in terms of age, gender, race, BMI, treatment for HTN, current CD4 cell count,
and time since HIV diagnosis across the three vitamin D groups (Table 1). Other characteris-
tics were similar across the groups, including smoking status, intravenous drug use as an HIV
transmission risk factor, and the prevalence of diabetes, hyperlipidemia, and chronic hepatitis.
Clinical characteristics also did not differ by vitamin D status, including nadir CD4 T-cell
count, a prior AIDS diagnosis, and HIV VL< 400 copies/mL that were similar across the
cohort regardless of vitamin D level. There were significantly more patients with vitamin D
insufficiency and deficiency who were prescribed an NNRTI-based regimen, whereas more
Vitamin D replete patients were prescribed Protease Inhibitor (PI) based regimens. Among
participants prescribed a NNRTI, 68% were prescribed efavirenz whereas among participants
prescribed a PI, 42% were prescribed atazanavir and 40% lopinavir.
Plasma biomarkers
Vitamin D was significantly inversely correlated with plasma levels of D-dimer, IL-6, and
TNF-α. (p<0.001 for each, Fig 1A and S1A Fig). Vitamin D-deficient participants compared
Vitamin D and monocyte activation
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Table 1. Participant characteristics, the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy, United States, 2004–
2006 (n = 663).
Vitamin D Level at Enrollment
Normal Insufficient Deficient P-value
( 30ng/mL) (20–29 ng/mL) (< 20 ng/mL)
No. People 190 (28.7%) 222 (33.5%) 251 (37.9%)
(% of Total Participants)
n (%) n (%) n (%)
Male Gender 158 (83.2) 176 (79.3) 170 (67.7) <0.001
Race <0.001
• White 148 (77.9) 140 (63.1) 95 (37.8)
• Black 26 (13.7) 54 (24.3) 121 (48.2)
• Other 16 (8.4) 28 (12.6) 35 (13.9)
Diabetic 12 (6.3) 20 (9.0) 27 (10.8) 0.27
Hypertensive 46 (24.2) 76 (34.2) 88 (35.1) 0.03
On treatment for HTN 23 (12.1) 49 (22.1) 54 (21.5) 0.02
On treatment for HDL 16 (8.4) 22 (9.9) 17 (6.8) 0.47
Prior AIDS 52 (27.4) 49 (22.1) 62 (24.7) 0.46
Current smoker* 87 (46.5) 90 (41.7) 108 (44.4) 0.61
Injection drug* use 24 (12.8) 34 (15.7) 30 (12.3) 0.53
On ART1 153 (80.5) 180 (81.1) 190 (75.7) 0.43
• NNRTI based2 57 (37.3) 89 (49.4) 109 (57.4) 0.001
• PI based2 93 (60.8) 78 (43.3) 67 (35.3) <0.0001
• Abacavir-containing2 61 (39.9) 66 (36.7) 62 (32.6) 0.19
• Tenofovir-containing2 99 (64.7) 95 (52.8) 88 (46.3) 0.001
HIV RNA (< 400 c/mL2)* 139 (90.8) 158 (88.3) 166 (87.8) 0.65
Not on ART 37 (19.5) 42 (18.9) 61 (24.3)
• Prior Use3 9 (24.3) 21 (50.0) 33 (54.1) 0.02
• No prior use3 28 (75.7) 21 (50.0) 28 (45.9)
Median [IQR] Median [IQR] Median [IQR]
Age (years) 41 [36, 46] 42 [36, 49] 40 [33, 46] 0.02
Body mass index (kg/m2) 25 [23, 27] 26 [23, 29] 27 [23, 31] <0.01
Nadir CD4 cell count 192 [60, 311] 205 [107, 310] 216 [90, 333] 0.37
(cells/mm3)
Current CD4 cell count 431 [322, 619] 498 [349, 729] 473 [331, 693] 0.01
(cells/mm3)
Duration on ART (months)
Current ART 26 [12, 59] 33 [15, 70] 41 [15, 65] 0.08
Prior ART 9 [3, 42] 34 [12, 44] 19 [8, 47] 0.47
Time since HIV diagnosis 46 [19, 93] 62 [28, 95] 62 [32, 101] 0.01
(months)
Values reported as N (%), or Median [IQR = interquartile range]
Chi-squared test of proportions or Kruskall Wallis non-parametric tests
1 Rows are not mutually exclusive
2 Among patients on ART
3 Among participants not on ART
*Missing variable data with new denominator:
Current smoker: Normal = 187, Insufficient = 216, Deficient = 243
Injection Drug Use: Normal = 187, Insufficient = 216, Deficient = 243
HIV VL <400: Insufficient = 179, Deficient = 189
HTN = Hypertension, HDL = High-density lipoprotein, ART = Antiretroviral therapy, NNRTI = Nonnucleoside reverse transcriptase inhibitor, PI = Protease
Inhibitor
https://doi.org/10.1371/journal.pone.0175517.t001
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with patients who had normal and insufficient levels had increased levels of D-dimer (24%;
p = 0.04), IL-6 (23%; p<0.01), and TNF-α (21%; p = 0.04) (Table 2). Levels of other plasma
biomarkers did not differ significantly between those with deficient versus non-deficient vita-
min D status.
Fig 1. Baseline spearman correlations with vitamin D levels. A) Association of biomarkers with vitamin D
(Vitamin D levels are based upon the measured levels per patient, *p<0.01)) B) Association of monocyte
phenotypes with vitamin D (Vitamin D levels are based upon the measured levels per patient, * p<0.01).
https://doi.org/10.1371/journal.pone.0175517.g001
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In univariate logistic regression models, higher levels of D-dimer, IL-6, and TNF-α were
also associated with vitamin D deficiency (Table 3). After adjusting for known baseline differ-
ences among the vitamin D groups, only increased IL-6 was associated (p = 0.02) with vitamin
D deficiency, and for each doubling of IL-6 there is a 19% increase in the odds of being vitamin
D deficient.
Monocyte phenotypes
Vitamin D concentrations were significantly inversely correlated with the percentage of patrol-
ling monocytes (CD14dimCD16+) and specifically monocytes expressing the patrolling mono-
cyte-associated chemokine, CX3CR1+. Vitamin D concentrations were significantly correlated
with the percentage of classical monocytes (CD14++CD16-) and specifically monocytes ex-
pressing the classical-monocyte associated chemokine, CCR2+ (Fig 1B and S1B Fig). Vitamin
D-deficient participants compared with those with normal and insufficient levels, had an
increased proportion of CD14dimCD16+ monocytes (22%; p<0.01), increased proportion of
Table 2. Geometric means (with 95% CI) of plasma biomarkers, monocytes and T-cell phenotypes, by vitamin D levels and percent difference of
deficient to those not deficient, at study enrollment, the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy, United
States, 2004–2006
Vitamin D Level at Enrollment
Normal Insufficient Deficient % Difference1 P-value2
( 30 ng/mL) (20–29 ng/mL) (< 20 ng/mL)
Plasma Biomarkers
D-Dimer (mg/L) 0.2 [0.2, 0.2] 0.2[0.2, 0.3] 0.3 [0.2, 0.3] 19.1 [0.6, 41.1] 0.04
IL-6 (pg/mL) 1.2 [1.1, 1.4] 1.3[1.2, 1.5] 1.5 [1.4, 1.7] 23.3 [6.4, 42.9] <0.01
IL-8 (pg/mL) 16.2 [14.2, 18.5] 15.5 [13.9, 17.4] 15.2 [13.7, 16.9] -4.0 [-16.3, 10.2] 0.56
TNF-α (pg/mL) 17.3 [14.9, 20.1] 19.1 [16.6, 21.9] 21.7 [18.9, 24.8] 18.8 [0.5, 40.6] 0.04
hsCRP (mg/L) 2.0 [1.7, 2.3] 2.2 [1.9, 2.5] 2.3 [2.0, 2.6] 8.0 [-10.3, 30.1] 0.42
sCD14 (ng/mL) 1169.1
[1127.6, 1212.1]
1127.3
[1089.6, 1166.3]
1149.3
[1106.7, 1193.6]
0.3 [-4.0, 4.7] 0.91
sCD163 (pg/mL) 542.1
[498.3, 589.8]
578.0
[522.2, 639.8]
539.6
[481.6, 604.5]
-4.1 [-15.4, 8.7] 0.51
Monocyte phenotypes
(% of Monocytes)
% CD14++CD16+ 5.1 [4.6, 5.6] 4.9 [4.4, 5.4] 5.2 [4.8, 5.7] 3.3 [-7.1, 14.9] 0.55
% CD14+CD16- 77.3 [75.5, 79.1] 75.8 [73.0, 78.7] 75.3 [73.9, 76.8] -1.5 [-4.7, 1.8] 0.36
% CD14dimCD16+ 5.4 [4.9, 6.1] 5.6 [5.0, 6.3] 6.7 [6.1, 7.4] 20.0 [5.4, 36.7] <0.01
% CCR2+ 88.5 [87.5, 89.6] 88.6 [87.6, 89.6] 85.6 [84.4, 86.8] -3.4 [-4.8, -1.9] <0.001
% CX3CR1+ 5.3 [4.5, 6.1] 5.4 [4.7, 6.2] 7.4 [6.6, 8.3] 45.1 [24.7, 68.8] <0.001
% TF+ 1.9 [1.7, 2.2] 1.9 [1.6, 2.2] 1.7 [1.5, 1.9] -12.7 [-26.3, 3.4] 0.12
T-cell phenotypes
(% of CD4 and CD8)
% CD4+CD38+DR+ 8.2 [7.3, 9.2] 8.4 [7.6, 9.3] 8.2 [7.4, 9.0] -2.1 [-13.6, 10.9] 0.74
% CD8+CD38+DR+ 20.0 [17.8, 22.4] 18.7 [17.1, 20.4] 19.9 [18.1,21.9] 1.9 [-9.1, 14.2] 0.75
% CD4+CD28-CD57- 2.0 [1.7, 2.3] 1.9 [1.6, 2.3] 1.7 [1.5, 2.0] -10.9[-28.3,10.6] 0.30
% CD8+CD20-CD57- 27.5 [25.5, 29.7] 26.1 [24.5, 27.9] 26.0 [24.2, 28.0] -2.7 [-10.7, 6.0] 0.53
Data are mean and 95% Confidence Interval.
1Percent difference comparing Vitamin D deficient to those not deficient.
2P-values are from general linear models
https://doi.org/10.1371/journal.pone.0175517.t002
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CX3CR1+ monocytes (48%; p<0.001), but a lower proportion of CCR2+ monocytes (-3.4%;
p< 0.001; Table 2).
In univariate logistic regression models, we found that increased expression of CX3CR1+
(p<0.01) and decreased expression of CCR2+ (p< 0.01) were significantly associated with
vitamin D deficiency (Table 3). In fully adjusted models associations with vitamin D deficiency
persisted for CCR2+ and CX3CR1+.
T-cell phenotypes
T-cell subsets were analyzed for markers of immune activation and senescence. There were no
significant associations between these markers and vitamin D levels. (Table 2 and Table 3).
Discussion
In this study, we explored associations between vitamin D status and levels of soluble and cel-
lular biomarkers of inflammation that predict clinical risk of mortality and non-AIDS-defining
complications among participants in a contemporary cohort of HIV-infected persons at low
risk for AIDS. As our understanding of the complex role vitamin D plays in regulating innate
and adaptive immune responses evolves, identifying the cellular targets of the active form of
vitamin D and the relationship with inflammatory biomarkers is an important step. Recent
studies have implicated 25(OH)D deficiency in HIV disease progression and death[1], and
Table 3. Association of biomarkers and immune phenotypes with vitamin D deficiency, the Study to Understand the Natural History of HIV/AIDS in
the Era of Effective Therapy, United States, 2004–2006
Unadjusted Odds Ratio Adjusted Odds Ratio
Odds Ratio (95%CI) P-value Odds Ratio (95%CI) P-value*
Plasma Biomarkers
D-dimer (mg/L) 1.25 (1.05, 1.49) 0.01 1.14 (0.94, 1.38) 0.19
IL-6 (pg/mL) 1.18 (1.04, 1.35) 0.01 1.19 (1.03, 1.39) 0.02
IL-8 (pg/mL) 0.96 (0.83, 1.10) 0.56 0.96 (0.83, 1.12) 0.61
TNF-α (pg/mL) 1.11 (1.00, 1.24) 0.05 1.03 (0.92, 1.15) 0.63
hsCRP (mg/L) 1.04 (0.95, 1.15) 0.40 0.94 (0.84, 1.06) 0.31
sCD14 (ng/mL) 1.02 (0.69, 1.52) 0.91 1.24 (0.79, 1.95) 0.35
sCD163 (pg/mL) 0.95 (0.81, 1.11) 0.53 0.88 (0.73, 1.05) 0.16
Monocyte Phenotypes
% CD14++CD16+ 1.06 (0.91, 1.24) 0.45 1.02 (0.86, 1.21) 0.81
% CD14+CD16- 0.79 (0.47, 1.32) 0.36 1.04 (0.60, 1.81) 0.89
% CD14dimCD16+ 1.23 (1.07, 1.41) <0.01 1.06 (0.91, 1.24) 0.44
% CCR2+ 0.07 (0.02, 0.24) <0.001 0.16 (0.04, 0.62) <0.01
% CX3CR1+ 1.29 (1.14, 1.47) <0.001 1.19 (1.04, 1.36) <0.01
% TF+ 0.92 (0.82, 1.02) 0.11 0.91 (0.81, 1.03) 0.13
T-cell Phenotypes
% CD4 CD38+DR+ 0.99 (0.86, 1.13) 0.88 1.02 (0.87, 1.18) 0.83
% CD8 CD38+DR+ 1.04 (0.90, 1.20) 0.60 1.05 (0.89, 1.24) 0.56
% CD4 CD28-CD57- 0.94 (0.86, 1.03) 0.21 0.97 (0.88, 1.07) 0.56
% CD8 CD28-CD57- 0.94 (0.77, 1.15) 0.54 1.02 (0.81, 1.28) 0.89
Deficient Vitamin D is value <20
*Adjusted for age, male gender, white race, BMI, treatment for HTN, NNRTI regimen, CD4 cell count, and time since HIV diagnosis
CI = Confidence Interval, BMI = Body Mass Index, HTN = Hypertension, NNRTI = Nonnucleoside reverse transcriptase inhibitor
https://doi.org/10.1371/journal.pone.0175517.t003
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further work has associated the phenotype of vitamin D deficiency with soluble markers of
inflammation that predict mortality [2, 3].
Here, we evaluated cellular phenotypes that may link vitamin D and biomarkers of inflam-
mation with clinical endpoints in chronic treated HIV infection. In univariate analysis, we
demonstrated an association of D-dimer, IL-6 and TNF-α with vitamin D deficiency, suggest-
ing a relationship between vitamin D and inflammation.
Among patients with vitamin D deficiency, we also found higher percentages of patrolling
monocytes (CD14dimCD16+), which typically express high levels of CX3CR1, and lower per-
centages of the classical monocyte subset (CD14++CD16-) that typically express CCR2 overall.
After adjustment, greater expression of CX3CR1 and lower expression of CCR2 remained sig-
nificantly associated with vitamin D deficiency. The finding of diminished CCR2 expression
was consistent with prior findings suggesting a downregulation of CCR2 with systemic inflam-
mation[6, 11]. The increase of CX3CR1 on monocytes has also been associated with systemic
inflammation in HIV [11, 12]. These shifts in monocyte phenotypes demonstrate a potential
link between vitamin D deficiency and immune activation.
In contrast to other reports, we did not observe an increase in activated T-cell phenotypes
associated with vitamin D deficiency [13], however, our participants included Americans of
different ethnicities, without excluding skin phototypes, which could play a role in the differ-
ences in T-cell phenotypes we observed.
Vitamin D deficiency is prevalent in both the general and HIV-infected populations[10],
and we report a prevalence of more than 35% in the present analysis. 25(OH)D deficiency has
been reported to increase susceptibility to tuberculosis and other infectious diseases [14], as
well as a variety of chronic diseases, including bone disease, muscle weakness, diabetes, cardio-
vascular disease, and some malignancies in HIV-uninfected persons [15, 16]. However, the
implications for persons with chronic HIV infection who are at relatively low risk for tubercu-
losis or other opportunistic infections have not been as well studied. Active forms of vitamin D
and its prohormone can regulate maturation of innate immune cells, including monocytes
and dendritic cells [17]. The extent to which vitamin D supplementation may affect monocyte
function, cytokine production, or chronic inflammation in the absence of acute and uncon-
trolled mycobacterial infection is unknown [17].
Our study was limited by the lack of an HIV-uninfected control group, which would be use-
ful to determine whether these immunologic associations differ by HIV infection status. We
could infer neither causation nor control for unmeasured confounding because of the cross-
sectional and non-randomized study design. The SUN Study also did not have sufficient num-
bers of participants or follow-up time to study associations directly with rates of clinical
events.
Vitamin D insufficiency and deficiency were prevalent in this U.S. HIV cohort with high
CD4 cell counts and high levels of viral suppression. Deficient levels of vitamin D were inde-
pendently associated with activated monocyte phenotypes. The role of vitamin D deficiency in
persistent immune activation and associated complications during chronic HIV disease should
be further evaluated and considered as a possible target for intervention.
Supporting information
S1 Fig. Scatterplots of biomarkers and monocyte phenotypes. S1 Fig A demonstrates scatter
plots of biomarkers by vitamin D and S1 Fig B demonstrates scatter plots of monocyte pheno-
types by vitamin D.
(TIFF)
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